Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine

J Mass Spectrom. 2005 Dec;40(12):1521-5. doi: 10.1002/jms.939.

Abstract

A method was developed and validated for the analysis of R(-)-apomorphine, (R-)-apocodeine and R(-)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid-liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1-100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor.

Publication types

  • Validation Study

MeSH terms

  • Apomorphine / analogs & derivatives*
  • Apomorphine / analysis*
  • Apomorphine / blood
  • Apomorphine / pharmacokinetics
  • Apomorphine / urine
  • Catechol O-Methyltransferase Inhibitors
  • Catechols / therapeutic use
  • Gas Chromatography-Mass Spectrometry / methods*
  • Humans
  • Nitriles
  • Parkinson Disease / drug therapy
  • Reproducibility of Results

Substances

  • Catechol O-Methyltransferase Inhibitors
  • Catechols
  • Nitriles
  • norapomorphine
  • entacapone
  • Apomorphine
  • apocodeine